Immunology & allergy
Immune system & allergy clinical trials
Autoimmune conditions, allergies, and disorders of the body’s immune defenses. We’re tracking 6,062 recruiting studies in this area right now.
By phase
- Not applicable3,004
- Phase 21,058
- Phase 1794
- Phase 1/Phase 2439
- Phase 3436
- Phase 4233
- Phase 2/Phase 398
Top conditions
- Multiple Sclerosis329
- Multiple Myeloma328
- Asthma193
- Lymphoma178
- Rheumatoid Arthritis131
- Type 1 Diabetes131
- Atopic Dermatitis124
- Systemic Lupus Erythematosus119
- Acute Lymphoblastic Leukemia118
- HIV Infections106
- Chronic Lymphocytic Leukemia96
- Autoimmune Diseases77
- Follicular Lymphoma70
- Rheumatoid Arthritis (RA)68
- Hodgkin Lymphoma64
- Diabetes Mellitus, Type 163
- Leukemia63
- Type 1 Diabetes Mellitus63
Leading sponsors
- National Institute of Allergy and Infectious Diseases (NIAID)97
- Institute of Hematology & Blood Diseases Hospital, China85
- National Cancer Institute (NCI)74
- Assistance Publique - Hôpitaux de Paris65
- AstraZeneca63
- M.D. Anderson Cancer Center58
- Novartis Pharmaceuticals58
- Mayo Clinic50
- City of Hope Medical Center48
- Memorial Sloan Kettering Cancer Center45
Where studies are running
- California497
- Maryland199
- Alabama177
- Florida152
- Arizona148
- Massachusetts117
- New York116
- Texas112
- Colorado82
- Illinois82
Recruiting studies6,062 total
- NCT07363590RecruitingPhase 1
Study of MK-1045 for lupus or rheumatoid arthritis
This study tests a new drug, MK-1045, for people with lupus or rheumatoid arthritis. It aims to see if the drug is safe and how it affects your condition.
Southport, QueenslandAges 18–75 - NCT07368270RecruitingPhase 1
Anti-PD1 armored CAR-T cells for adults with relapsed/refractory DLBCL
This trial tests a new kind of cell therapy that combines CAR-T cells (which find and kill cancer cells) with an anti-PD1 'armor' to boost their power. It is for adults with diffuse large B-cell lymphoma (DLBCL) that has come back or not responded to earlier treatments.
SuzhouAges 18 years+ - NCT07369895RecruitingPhase 1
A new cell therapy for relapsed or refractory multiple myeloma
This trial tests a new cell therapy (O&D-001) for multiple myeloma that has returned or not responded to previous treatments. It targets specific markers on myeloma cells (BCMA or GPRC5D) and aims to shrink the cancer.
Guangzhou, GuangdongAges 18–75 - NCT07369492RecruitingPhase 1
Study of BAFF-R CAR-T cells for CD19-negative B-cell lymphoma
This trial tests a new type of immunotherapy called BAFF-R CAR-T cells for people with B-cell lymphoma that has come back or not responded to treatment, and whose cancer cells do not have the CD19 protein. The treatment uses your own immune cells, modified to target and kill the lymphoma cells.
SuzhouAges 18 years+ - NCT06845722Recruiting
Balance and cognitive training for multiple sclerosis
This trial tests whether combining balance exercises with brain-training activities can help improve walking and thinking in people with multiple sclerosis. It is for people aged 40–55 who have mild cognitive problems and balance issues.
LahoreAges 40–55 - NCT06718920Recruiting
Childhood experiences and quality of life in MS
This study looks at how difficult childhood experiences may affect the quality of life and coping skills of people with multiple sclerosis. By answering questionnaires, you can help researchers understand these connections and find better ways to support patients.
Rome, RMAges 18 years+ - NCT06838884Recruiting
A 6-minute step test for people with rheumatoid arthritis
This study is testing a simple, 6-minute step test as a way to assess physical function in people with rheumatoid arthritis. The goal is to see if stepping in place can be a helpful alternative to walking tests.
Merkez, ElâzığAges 18 years+ - NCT06846905Recruiting
Cost and effects of raising the dose of myeloma drugs at home vs. hospital
This study compares whether raising the dose of your current bispecific antibody is more cost-effective when done as an outpatient (day hospital) or as an inpatient. It aims to find the best way to manage your treatment safely.
ToulouseAges 18 years+ - NCT06173219RecruitingPhase 1/Phase 2
Radiation and immunotherapy for advanced cancer
This trial tests combining two types of radiation therapy with an immunotherapy drug for people with advanced solid tumors that have spread or come back. The goal is to see if this approach can help when standard treatments have stopped working or aren’t an option.
Beijing, Beijing MunicipalityAges 18–75 - NCT06848608Recruiting
Yoga vs. physical therapy for sarcoidosis fatigue
This study compares the benefits of yoga versus standard physical therapy for people with sarcoidosis who have lung involvement and fatigue. It aims to find which approach better helps manage symptoms and improve daily life.
Istanbul, MaltepeAges 18–75 - NCT07355218RecruitingPhase 3
Testing enpatoran for lupus skin problems
This trial tests an oral drug called enpatoran for people with lupus that causes skin rashes (like discoid or subacute cutaneous lupus). The goal is to see if the drug can improve these skin symptoms.
Upland, CaliforniaAges 18–75 - NCT07356089Recruiting
Twiist insulin pump study for type 1 diabetes
This study follows people with type 1 diabetes who are already using the Twiist automated insulin delivery system. Researchers will ask you to complete surveys and share data for 12 months to check how well the system works in everyday life.
Tampa, FloridaAges 6 years+ - NCT07358780Recruiting
Remibrutinib study for chronic hives
This study observes how well remibrutinib works for people with chronic hives (CSU) in everyday medical practice. It compares three groups based on treatments you have tried, and checks if switching to remibrutinib helps control symptoms.
Kirksville, MissouriAges 18–100 - NCT07358364Recruiting
Remibrutinib in real-world chronic hives
This study follows people with chronic hives (CSU) who start taking remibrutinib as part of their normal care. It looks at how well the medicine works in real life over 24 months.
Kirksville, MissouriAges 18 years+ - NCT07360080Recruiting
Long-Term Effects of Teplizumab in Real-World Care
This study follows people who have already received teplizumab (a treatment to delay type 1 diabetes) to see how they do over time. It aims to understand the long-term effects in routine care.
Atlanta, GeorgiaAges Any age - NCT07356713RecruitingPhase 1
Finding the right dose of EXL-111 for healthy volunteers
This trial tests a new drug called EXL-111 in healthy people to find the safest and best dose for future studies. It may help people with allergies if the drug proves effective.
Adelaide, South AustraliaAges 18–55 - NCT07354932RecruitingPhase 2
Testing SHR-2173 for IgA Nephropathy
This trial tests a new drug, SHR-2173, for people with IgA nephropathy who still have a lot of protein in their urine despite standard care. The goal is to see if it can help protect kidney function.
Guangzhou, GuangdongAges 18 years+ - NCT07358156RecruitingPhase 1
Comparing a new dupilumab medicine to Dupixent in healthy adults
This trial tests a new version of Dupixent® (called CKD-706) to see how it compares to the approved medicine in healthy adults. It's a first step to make sure the new medicine works similarly and is safe.
Berlin, State of BerlinAges 18–55 - NCT07355075RecruitingPhase 2/Phase 3
Study of a new cream for moderate to severe eczema
This study tests an investigational cream for moderate to severe eczema. It helps see if the cream reduces symptoms like itching and skin inflammation.
Irving, TexasAges 18–80 - NCT06849193Recruiting
Predicting treatment outcomes in advanced bile duct cancer
This study looks at how well current chemotherapy and immunotherapy work for advanced bile duct or gallbladder cancers that cannot be removed by surgery. Researchers will collect data from multiple centers to build a model that helps predict how patients may respond to treatment.
Nanjing, JiangsuAges 18 years+ - NCT07359430Recruiting
Deep phenotyping of chronic inducible urticaria
This study aims to better understand inducible urticaria (hives triggered by cold, pressure, or friction) and chronic spontaneous urticaria. Researchers will use skin tests to measure how different triggers affect your skin in detail.
Leiden, South HollandAges 18 years+ - NCT07359859RecruitingPhase 2
Ruxolitinib to prevent GVHD in stem cell transplant
This trial tests whether the drug ruxolitinib, given before and after a stem cell transplant, can help prevent graft-versus-host disease (GVHD) in people with blood cancers. GVHD is a common complication where donor cells attack the patient's body.
Basking Ridge, New JerseyAges 18 years+ - NCT07360886Recruiting
Early detection of brain conditions in active drivers
This study looks at how well doctors can spot early signs of certain brain conditions in people who drive. You may join if you have a valid license, are between 18 and 85, and have one of the neurological diagnoses the study is focusing on.
Olomouc, Olomouc RegionAges 18–85 - NCT07358234Enrolling by invitationEarly Phase 1
Comparing two EoE treatments on esophagus widening
This study compares two medicines—Eohilia (an oral steroid) and Dupixent (an injectable biologic)—to see which one better helps widen the esophagus in people with eosinophilic esophagitis (EoE). It may help you if you have active EoE and are looking for a new treatment option.
Scottsdale, ArizonaAges 18 years+
Common questions
- How many immune system & allergy clinical trials are recruiting?
- Clin2 is tracking 6,062 recruiting immunology & allergy studies from the U.S. registry right now, out of 9,151 we cover in this area in total.
- What does “Immune system & allergy” cover here?
- Autoimmune conditions, allergies, and disorders of the body’s immune defenses. We group each study into immune system & allergy based on the conditions it studies, so you can scan the whole therapeutic area at once and drill into a specific condition.
- How do I find a immune system & allergy trial near me?
- Use the search to filter immune system & allergy studies by location and eligibility. Every Clin2 trial page explains the criteria in plain English and offers a short, optional pre-screen for a fit read — the study team makes the final decision.
Other specialties
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov; specialty groupings are derived from each study’s conditions. Talk with your doctor about whether a specific trial is right for you.